C4 Therapeutics, Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company focused on targeted protein degradation and oncology drug development. Its 8-K reports cover material agreements, including the Roche research collaboration and license agreement for degrader-antibody conjugates, clinical and regulatory disclosures, operating results, business updates, and capital-structure matters involving common stock sales arrangements.
Proxy and governance filings describe board matters, executive compensation, equity awards, shareholder voting items, and by-law provisions, including forum-selection amendments. The filing record also includes Regulation FD disclosures, clinical presentation exhibits for cemsidomide, and other material-event reports tied to the company’s pipeline, collaborations, and public-company governance.
C4 Therapeutics Chief Medical Officer Leonard Reyno reported multiple equity compensation transactions in company stock. On February 13, 2026, he received a grant of 240,000 restricted stock units (RSUs), with 120,000 RSUs vesting in three equal annual installments starting on February 13, 2027, and 120,000 RSUs vesting in full on February 13, 2029, subject to potential performance-based acceleration.
On February 14, 2026, previously disclosed RSU awards vested, resulting in the acquisition of 30,950 shares of common stock at no cost. On the same date, 16,579 shares were withheld by the company at $1.89 per share to cover tax obligations related to the RSU vesting, which the filing states does not represent a sale. Following these transactions, Reyno directly owned 379,803 shares of common stock.
C4 Therapeutics, Inc. reported insider equity activity by Chief Financial Officer Kendra Adams. She received a grant of 240,000 restricted stock units (RSUs), which vest in stages through February 13, 2029, based on time and performance conditions.
Adams also acquired 30,950 and 3,750 shares of common stock through vesting and exercise of previously granted RSUs, and 15,381 and 1,863 shares were withheld by the company at $1.89 per share to cover tax obligations. After these transactions, she directly holds 385,098 shares of common stock.
C4 Therapeutics Chief Accounting Officer Mark Mossler reported equity compensation and related share movements. He received a grant of 56,980 restricted stock units, each representing one future share of common stock upon vesting and settlement.
According to the grant terms, 28,490 RSUs vest in three equal annual installments starting on February 13, 2027, and 28,490 RSUs vest in full on February 13, 2029, subject to performance milestones. Separately, 9,420 shares of common stock were acquired upon vesting of previously disclosed RSU awards, while 3,268 shares were withheld by the company at a price of $1.89 per share to cover tax obligations, which the filing specifies is not a sale. After these transactions, Mossler directly holds 71,916 shares of common stock.
C4 Therapeutics, Inc. received an amended Schedule 13G/A showing updated ownership by OrbiMed entities. OrbiMed Advisors LLC reports beneficial ownership of 521,368 shares of common stock, representing 0.5% of the class. OrbiMed Capital LLC reports 883,534 shares, or 1.0% of the class.
Together, the reporting persons hold 1.5% of C4 Therapeutics’ common stock on behalf of other persons who have rights to dividends or sale proceeds. Investment and voting power is exercised through a management committee, whose individual members disclaim beneficial ownership. The securities are described as acquired and held in the ordinary course of business, not to influence control.
Lynx1 Capital Management LP and Weston Nichols report a 7.3% beneficial stake in C4 Therapeutics, Inc. common stock, totaling 7,098,133 shares. This percentage is based on 96,914,418 shares outstanding as of October 29, 2025, from the company’s Form 10‑Q for the quarter ended September 30, 2025.
The shares are directly held by Lynx1 Master Fund LP, which has the right to receive dividends and sale proceeds, while Lynx1 Capital Management LP serves as investment manager and Weston Nichols is its control person. The reporting parties certify the holdings were not acquired to change or influence control of C4 Therapeutics.
C4 Therapeutics, Inc. shareholder update: a group of Soleus investment entities filed an amended Schedule 13G/A reporting passive ownership of C4 Therapeutics common stock.
Soleus Capital Management, L.P., Soleus GP, LLC and Guy Levy each report beneficial ownership of 10,334,114 shares, representing 9.99% of the outstanding common stock based on 96,914,418 shares as of October 29, 2025. This total includes warrants to purchase up to 6,530,172 shares, subject to beneficial ownership limitations in those warrants. Other Soleus entities, including Soleus Private Equity Fund III, L.P., report 6,072,822 shares, or 5.9% of the class, including warrants to purchase up to 5,822,829 shares.
The filing states the securities were not acquired and are not held for the purpose of changing or influencing control of C4 Therapeutics, and multiple Soleus entities and Guy Levy disclaim beneficial ownership beyond Section 13(d) reporting obligations.
Morgan Stanley and Morgan Stanley & Co. LLC report a significant passive stake in C4 Therapeutics, Inc. common stock. They beneficially own 8,974,191 shares, representing 9.3% of the class as of 12/31/2025, with all voting and dispositive power held on a shared basis.
The firms state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of C4 Therapeutics.
C4 Therapeutics Chief Medical Officer Leonard Reyno reported an open-market sale of company stock. On January 16, 2026, he sold 10,000 shares of C4 Therapeutics, Inc. common stock at a price of $2.22 per share, as shown by transaction code "S" for a disposition. After this trade, he directly beneficially owns 156,382 shares of the company’s common stock.
C4 Therapeutics, Inc. filed a Form 8-K to furnish information about a new corporate update. On January 14, 2026, the company issued a press release that outlines its milestones through 2028 and highlights recent achievements, and has attached this press release as Exhibit 99.1.
The disclosure is made under Item 7.01 (Regulation FD Disclosure), which means the information in the press release and Item 7.01 is being furnished rather than filed and is not subject to certain liability provisions of the Exchange Act or automatically incorporated into other securities law filings. The report is signed on behalf of the company by its Chief Financial Officer and Treasurer, Kendra R. Adams.
C4 Therapeutics, Inc. is filing a shelf registration statement to offer up to $400,000,000 of common stock, preferred stock, debt securities, warrants and units. This includes a sales agreement prospectus for up to $125,000,000 of common stock that may be issued from time to time through TD Securities (USA) LLC under an at-the-market program, which is part of the $400,000,000 total.
The company is a clinical-stage biopharmaceutical developer focused on targeted protein degradation, led by its cemsidomide program in multiple myeloma and non-Hodgkin lymphoma, where Phase 1 data have shown generally well-tolerated profiles and anti-tumor activity. In an October 2025 underwritten offering, C4 Therapeutics raised approximately $117.0 million in net proceeds and structured additional potential proceeds through pre-funded and other warrants. The shelf registration is intended to provide flexible access to capital for general corporate purposes, including research and development and pipeline expansion.